REX AI Equity Premium Income ETF vs Ginkgo Bioworks Holdings Inc — how do they compare? REX AI Equity Premium Income ETF trades at $37.42, while Ginkgo Bioworks Holdings Inc trades at $7.25 (market cap $505.73M). The key difference: REX AI Equity Premium Income ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AIPI | DNA | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $16.14 |
52-Week Low | $32.45 | $5.48 |
Market Cap | — | $505.73M |
Enterprise Value | — | $607.68M |
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.42, up 0.21% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock exhibits a high distribution yield strategy, paying weekly dividends, with recent payouts ranging from $0.23 to $0.26. Support and resistance are tightly clustered around $37-$38, indicating potential volatility. Recent news highlights the fund's transition to weekly distributions and questions about sustainability amid AI market dynamics.
The outlook for AIPI hinges on its ability to sustain high yields through its option-writing strategy, though structural risks and NAV erosion concerns persist. Investment opportunity lies in income generation, but risks include dependency on AI sector performance and capped upside. Analyst sentiment is mixed, with some caution over long-term viability.
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
Trailing returns across standard periods
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →